AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging

The article describes ISM9077 as a dual-purpose, potential first-in-class pipeline candidate aimed at ocular diseases, inflammatory disorders, and aspects of the aging process. It notes the drug was designed and optimized using Chemistry42’s integrated generative chemistry capabilities, but provides no clinical efficacy, safety, or timeline milestones.

Analysis

The article describes ISM9077 as a dual-purpose, potential first-in-class pipeline candidate aimed at ocular diseases, inflammatory disorders, and aspects of the aging process. It notes the drug was designed and optimized using Chemistry42’s integrated generative chemistry capabilities, but provides no clinical efficacy, safety, or timeline milestones.